Want to see NVO full AI Analyst Report?
NVO Stock Chart & Stats
$48.77
$0.95(1.95%)
At close: 4:00 PM EDT
$48.77
$0.95(1.95%)
Day’s Range― - ―
52-Week Range$35.12 - $64.16
Previous CloseN/A
Volume1.15M
Average Volume (3M)10.13M
Market Cap
$209.64B
Enterprise Value$182.73K
Total Cash (Recent Filing)$21.63B
Total Debt (Recent Filing)$146.38B
Price to Earnings (P/E)11.2
Beta1.12
Next Earnings
Aug 05, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend Yield3.83%
Share Statistics
EPS (TTM)27.45
Shares Outstanding3,390,128,000
10 Day Avg. Volume8,396,881
30 Day Avg. Volume10,126,022
Financial Highlights & Ratios
PEG Ratio8.16
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio49.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$44.67Price Target Upside-8.41% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)3.28
Revenue Forecast (FY)$44.46B
Bulls Say, Bears Say
Bulls Say
Market Leadership In GLP-1 Obesity TreatmentsDominant market share and rapid prescription uptake create a durable competitive moat for obesity care. High share and broad patient adoption support scale advantages across manufacturing, payer negotiations and provider familiarity, anchoring long-term revenue despite competition.
Robust Pipeline And Regulatory ProgressA deep, advancing pipeline across obesity, diabetes, rare disease and cardiometabolic indications diversifies future revenue streams. Ongoing approvals and late‑stage programs de‑risk long‑term growth and extend product lifecycles beyond current GLP‑1 franchises.
Exceptional Profitability And MarginsSustained high gross and net margins reflect pricing power, efficient commercial scale, and a portfolio skewed to specialty branded medicines. Strong profitability underpins cash available for R&D, buybacks and dividends, supporting durable shareholder returns and reinvestment capacity.
Bears Say
Rising Leverage Reduces Financial FlexibilityMaterial increase in leverage weakens balance‑sheet flexibility and raises sensitivity to higher interest rates or earnings volatility. Higher debt limits optionality for opportunistic M&A or cushioning during cyclic downturns, increasing structural financial risk over coming quarters.
Weaker And Volatile Free Cash Flow ConversionDeclining and more volatile free cash flow reduces sustainably available capital for investment, dividends and buybacks. Persistent cash conversion weakness can force tradeoffs between R&D, commercial support and shareholder returns, constraining long‑term strategic flexibility.
Sustained Pricing And Access HeadwindsOngoing price erosion, reimbursement constraints and anticipated LOE effects create structural top‑line and margin pressure. Even with volume gains, lower realized prices and channel shifts can compress long‑term profitability and require sustained investment in access or volume to offset revenue loss.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $35.12 and its highest was $64.16 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $209.64B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Aug 05, 2026 which is tomorrow.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on May 06, 2026. The company reported $1.043 earnings per share for the quarter, beating the consensus estimate of $0.884 by $0.159.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $1.217 which represents an annual dividend yield of 3.83%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.77.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $1.043 in its last earnings report, beating expectations of $0.884. Following the earnings report the stock price went up 1.984%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$44.67 (-8.41% Downside)
$44.67 (-8.41% Downside)
Blogger Sentiment
Bullish
NVO Sentiment 77%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 21.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bearish
Bullish news 7%
Bearish news 93%
Bearish news 93%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.35%
12-Months-Change
Fundamentals
Return on Equity
3.83%
Trailing 12-Months
Asset Growth
21.75%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
NVO Company Deck
NVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights very strong commercial and clinical momentum—especially for the Wegovy franchise (oral and high‑dose launches), positive pivotal and Phase II readouts (Etavopivat, UBT251), significant prescription uptake and clear execution on launches and shareholder returns. However, these commercial and R&D successes are balanced by meaningful near‑term financial headwinds: adjusted sales and operating profit declines, margin pressure from lower realized prices, pricing and reimbursement pressures (U.S. and international), guidance implying negative group growth for 2026, and supply/inventory nuances. Overall, product and pipeline momentum is robust, but the company faces material pricing and market access challenges that temper the near‑term financial outlook.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$44.67
▼(-8.41% Downside)
Technical Analysis
Ownership Overview
―
Insiders
1.65% Mutual Funds
0.79% Other Institutional Investors
97.30% Public Companies and Individual Investors